Addition of both cetuximab and KTN3379 resulted in significantly increased growth inhibition in cetuximab-sensitive lines compared to each agent alone, suggesting that dual ErbB blockade results in improvedanti-tumor activity. Here, EGFR is linked to neoplasm.